UAE –The Imperial College London Diabetes Centre (ICLDC), a member of the M42 group, has inked two agreements to improve diabetes care by embracing advances in precision medicine, patient empowerment, and personalised care.
These agreements were signed on the second day of Arab Health, underscoring ICLDC’s commitment to innovation in healthcare.
The first agreement is with Medtronic, a global healthcare technology solutions provider.
ICLDC currently serves over 1,000 patients in Abu Dhabi who are using Medtronic’s CareLink™ platform.
With the new partnership, ICLDC will transition to Medtronic’s advanced CareConnect and GALAXY platforms, which offer enhanced features to improve diabetes management.
CareConnect is a user-friendly platform designed to be more patient-centric than the data-heavy CareLink™ dashboard.
It includes customizable notifications to alert caregivers about critical events, such as abnormal glucose levels or device issues.
This remote monitoring system allows for better follow-up care, reducing the need for in-person visits.
By prioritizing patient cases based on urgency, CareConnect helps ensure timely interventions, enabling physicians to manage patients remotely and provide consistent care.
The platform also facilitates real-time data sharing with family members and caregivers, improving response times to alerts and promoting faster action.
This is especially crucial for managing diabetes, a time-sensitive condition.
In addition to CareConnect, ICLDC will adopt Medtronic’s GALAXY platform, which provides tailored reporting and insights.
GALAXY enables clinicians to view aggregated patient data, offering a comprehensive understanding of patient health and supporting improvements in treatment outcomes.
As part of the collaboration, ICLDC is also teaming up with Karaz, an innovative healthcare platform that streamlines data integration.
Currently, caregivers need to access multiple platforms to retrieve data from various devices like insulin pumps and continuous glucose monitoring (CGM) systems.
Karaz will consolidate this data into a single, easy-to-use dashboard, enhancing workflow efficiency and allowing for a more holistic approach to patient care.
Its predictive insights, combined with GALAXY’s clinical analytics, will help healthcare providers anticipate patient needs and deliver better outcomes.
Dr. Mai Al Jaber, CEO of Outpatient Care at M42, commented on these agreements, describing them as transformative milestones in the effort to revolutionize diabetes care.
She emphasized that the partnership with Medtronic and Karaz is not just about adopting new technology; it’s about leading its integration to empower patients with more control over their health.
She added that this initiative is setting a new standard for proactive, personalized care, both locally and globally, and is crucial in the ongoing battle against diabetes.
Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on our WhatsApp channel for updates.
Be the first to leave a comment